Journal article
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region
Xavier Castellsague, Kevin A Ault, F Xavier Bosch, Darron Brown, Jack Cuzick, Daron G Ferris, Elmar A Joura, Suzanne M Garland, Anna R Giuliano, Mauricio Hernandez-Avila, Warner Huh, Ole-Erik Iversen, Susanne K Kjaer, Joaquin Luna, Joseph Monsonego, Nubia Munoz, Evan Myers, Jorma Paavonen, Punnee Pitisuttihum, Marc Steben Show all
PAPILLOMAVIRUS RESEARCH | ELSEVIER | Published : 2016
Abstract
BACKGROUND: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region METHODS: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. RESULTS: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type pre..
View full abstractGrants
Awarded by Merck and Co., Inc., Kenilworth, NJ
Awarded by Cancer Research UK
Funding Acknowledgements
This study was funded by Merck and Co., Inc., Kenilworth, NJ (ClinicalTrials.gov: NCT00092521, NCT00092534, and NCT00090220). This systematic review was designed, managed, and analyzed jointly by authors employed by Merck & Co. and external authors who were not paid for their work.